Works matching DE "DARBEPOETIN alfa"

Results: 84
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12

    Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study.

    Published in:
    Nephrology Dialysis Transplantation, 2016, v. 31, n. 12, p. 2073, doi. 10.1093/ndt/gfw047
    By:
    • Galle, Jan-Christoph;
    • Addison, Janet;
    • Suranyi, Michael G.;
    • Claes, Kathleen;
    • Di Giulio, Salvatore;
    • Guerin, Alain;
    • Herlitz, Hans;
    • Kiss, István;
    • Farouk, Mourad;
    • Manamley, Nick;
    • Wirnsberger, Gerhard;
    • Winearls, Christopher
    Publication type:
    Article
    13

    DIALYSIS ANAEMIA.

    Published in:
    Nephrology Dialysis Transplantation, 2014, v. 29, n. suppl_3, p. iii491, doi. 10.1093/ndt/gfu176
    Publication type:
    Article
    14

    An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study.

    Published in:
    Nephrology Dialysis Transplantation, 2012, v. 27, n. 6, p. 2303, doi. 10.1093/ndt/gfr677
    By:
    • Galle, Jan-Christoph;
    • Claes, Kathleen;
    • Kiss, Istvan;
    • Winearls, Christopher G.;
    • Herlitz, Hans;
    • Guerin, Alain;
    • Di Giulio, Salvatore;
    • Suranyi, Michael G.;
    • Bridges, Ian;
    • Addison, Janet;
    • Farouk, Mourad
    Publication type:
    Article
    15

    Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group.

    Published in:
    Leukemia & Lymphoma, 2016, v. 57, n. 3, p. 596, doi. 10.3109/10428194.2015.1079314
    By:
    • Goede, Valentin;
    • Busch, Raymonde;
    • Bahlo, Jasmin;
    • Chataline, Viktoria;
    • Kremers, Stephan;
    • Müller, Lothar;
    • Reschke, Daniel;
    • Schlag, Rudolf;
    • Schmidt, Burkhard;
    • Vehling-Kaiser, Ursula;
    • Wedding, Ulrich;
    • Stilgenbauer, Stefan;
    • Hallek, Michael
    Publication type:
    Article
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25

    High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.

    Published in:
    Annals of Hematology, 2013, v. 92, n. 5, p. 621, doi. 10.1007/s00277-013-1686-4
    By:
    • Kelaidi, C.;
    • Beyne-Rauzy, O.;
    • Braun, T.;
    • Sapena, R.;
    • Cougoul, P.;
    • Adès, L.;
    • Pillard, F.;
    • Lambert, C.;
    • Charniot, J.;
    • Guerci, A.;
    • Choufi, B.;
    • Stamatoullas, A.;
    • Slama, B.;
    • Renzis, B.;
    • Ame, S.;
    • Damaj, G.;
    • Boyer, F.;
    • Chaury, M.;
    • Legros, L.;
    • Cheze, S.
    Publication type:
    Article
    26
    27
    28
    29

    Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥10 g/dL: an exploratory analysis of a phase 3 trial.

    Published in:
    Medical Oncology, 2012, v. 29, n. 3, p. 2291, doi. 10.1007/s12032-011-0103-x
    By:
    • Canon, Jean-Luc;
    • Vansteenkiste, Johan;
    • Hedenus, Michael;
    • Gascon, Pere;
    • Bokemeyer, Carsten;
    • Ludwig, Heinz;
    • Vermorken, Jan;
    • Legg, Jason;
    • Pujol, Beatriz;
    • Bridges, Ken
    Publication type:
    Article
    30
    31
    32
    33
    34
    35

    Foreword.

    Published in:
    Nephrology Dialysis Transplantation, 2007, v. 22, n. suppl_4, p. iv1, doi. 10.1093/ndt/gfm159
    By:
    • Carrera, Fernando
    Publication type:
    Article
    36

    Pharmacology of darbepoetin alfa.

    Published in:
    Nephrology Dialysis Transplantation, 2007, v. 22, n. suppl_4, p. iv2, doi. 10.1093/ndt/gfm160
    By:
    • Macdougall, Iain C.;
    • Padhi, Desmond;
    • Jang, Graham
    Publication type:
    Article
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49

    Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial).

    Published in:
    Clinical & Experimental Nephrology, 2018, v. 22, n. 1, p. 78, doi. 10.1007/s10157-017-1427-4
    By:
    • Kato, Hideki;
    • Nangaku, Masaomi;
    • Hirakata, Hideki;
    • Wada, Takashi;
    • Hayashi, Terumasa;
    • Sato, Hiroshi;
    • Yamazaki, Yasushi;
    • Masaki, Takao;
    • Kagimura, Tatsuo;
    • Yamamoto, Hiroyasu;
    • Hase, Hiroki;
    • Kamouchi, Masahiro;
    • Imai, Enyu;
    • Mizuno, Kyoichi;
    • Iwasaki, Manabu;
    • Akizawa, Tadao;
    • Tsubakihara, Yoshiharu;
    • Maruyama, Shoichi;
    • Narita, Ichiei
    Publication type:
    Article
    50

    Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial).

    Published in:
    Clinical & Experimental Nephrology, 2016, v. 20, n. 1, p. 71, doi. 10.1007/s10157-015-1133-z
    By:
    • Imai, Enyu;
    • Maruyama, Shoichi;
    • Nangaku, Masaomi;
    • Hirakata, Hideki;
    • Hayashi, Terumasa;
    • Narita, Ichiei;
    • Kono, Hideki;
    • Nakatani, Eiji;
    • Morita, Satoshi;
    • Tsubakihara, Yoshiharu;
    • Akizawa, Tadao
    Publication type:
    Article